Experimental models of Alzheimer's disease (AD) are critical to gaining a better
understanding of pathogenesis and to assess the potential of novel therapeutic approaches …

Use of selective in-vivo tau imaging will enable improved understanding of tau aggregation
in the brain, facilitating research into causes, diagnosis, and treatment of major tauopathies …

Alzheimer's disease (AD) pathogenesis is widely believed to be driven by the production
and deposition of the amyloid-β peptide (Aβ). For many years, investigators have been …

The prion paradigm has emerged as a unifying molecular principle for the pathogenesis of
many age-related neurodegenerative diseases. This paradigm holds that a fundamental …

The accumulation of misfolded proteins (MP s), both unique and common, for different
diseases is central for many chronic degenerative diseases. In certain patients, MP …

Over 5 million Americans and 50 million individuals worldwide are living with Alzheimer's
disease (AD). The progressive dementia associated with AD currently has no cure. Although …

Aβ plaques are one of the two lesions in the brain that define the neuropathological
diagnosis of Alzheimer's disease. Plaques are highly diverse structures; many of them …

Objective: To investigate the particular pathology of the Arctic APP (APP arc) early-onset
familial Alzheimer disease (eoFAD) mutation for the first time in vivo with PET in comparison …

The detection and staging of Alzheimer's disease (AD) using non-invasive imaging
biomarkers is of substantial clinical importance. Positron emission tomography (PET) …

Nonhuman primates are useful for the study of age-associated changes in the brain and
behavior in a model that is biologically proximal to humans. The Aβ and tau proteins, two …